ArticleClinical, cosmetic and investigational dermatology2026
Complete Skin Clearance is Associated with HADS-Defined Absence of Anxiety and Depressive Symptoms After IL-17A Inhibitor Treatment in Moderate-to-Severe Psoriasis: Evidence from the SPEECH Cohort.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a chronic immune-mediated disease associated with anxiety, depressive symptoms, and impaired quality of life, potentially involving interacting psychosocial and inflammatory pathways. During biologic treatment, psychological symptoms may improve alongside skin disease, but whether complete skin clearance (CSC) is associated with Hospital Anxiety and Depression Scale (HADS)-defined absence of anxiety and depressive symptoms remains unclear. Objective: To examine whether CSC, defined as PASI100, was associated with HADS-defined absence of anxiety and depressive symptoms after 12-week IL-17A inhibitor treatment in moderate-to-severe psoriasis. Methods: Patients receiving IL-17A inhibitors were identified from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH). Eligible patients had complete baseline data, week-12 Psoriasis area and severity index (PASI) and HADS assessments. PASI responses represented percentage improvement from baseline and were categorized as PASI<75, PASI75-<100, or PASI100. The primary outcomes were week-12 HADS-A = 0 and HADS-D = 0, and the secondary outcomes were week-12 HADS-A and HADS-D as continuous outcomes. Logistic and linear regression, subgroup, and sensitivity analyses were performed. Results: Among 233 patients, 32 (13.7%) achieved PASI<75, 99 (42.5%) PASI75-<100, and 102 (43.8%) PASI100. Baseline HADS-A and HADS-D were comparable across groups. Compared with PASI100, PASI75-<100 was associated with lower odds of HADS-A = 0 (adjusted OR [aOR], 0.40; 95% confidence interval [CI], 0.20-0.78) and HADS-D = 0 (aOR, 0.48; 95% CI, 0.25-0.95), and higher week-12 HADS-A (adjusted β, 1.10; 95% CI, 0.34-1.86) and HADS-D (adjusted β, 0.95; 95% CI, 0.18-1.72). For PASI<75 versus PASI100, the corresponding aORs for HADS-A = 0 and HADS-D = 0 were 0.22 (95% CI, 0.08-0.62) and 0.27 (95% CI, 0.09-0.81), respectively. Subgroup and sensitivity analyses yielded consistent findings. Conclusion: CSC was associated with a higher likelihood of HADS-defined absence of anxiety and depressive symptoms in the treatment of moderate-to-severe psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.